Valuation: Filana Therapeutics, Inc.

Market Cap 2.36Cr 2.15Cr 1.98Cr 1.79Cr 3.38Cr 221.85Cr 3.5Cr 24Cr 9.45Cr 119.05Cr 8.87Cr 8.68Cr 377.1Cr P/E 2026 *
-0.55x
P/E 2027 * -0.41x
Enterprise Value 2.36Cr 2.15Cr 1.98Cr 1.79Cr 3.38Cr 221.85Cr 3.5Cr 24Cr 9.45Cr 119.05Cr 8.87Cr 8.68Cr 377.1Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.02%
Yield 2026 *
-
Yield 2027 * -
1 day+2.34%
1 week-0.48%
Current month-22.83%
1 month-29.62%
3 months-46.07%
6 months-59.66%
Current year-75.76%
1 week 0.39
Extreme 0.39
0.51
1 month 0.39
Extreme 0.39
0.71
Current year 0.39
Extreme 0.39
2.49
1 year 0.39
Extreme 0.39
3.45
3 years 0.39
Extreme 0.39
42.2
5 years 0.39
Extreme 0.39
62.49
10 years 0.39
Extreme 0.39
146.16
Manager TitleAgeSince
Chief Executive Officer 67 06/09/2024
Director of Finance/CFO 57 01/10/2018
Chief Tech/Sci/R&D Officer 70 07/08/2025
Director TitleAgeSince
Director/Board Member 78 07/12/2007
Chairman 67 17/07/2024
Chairman 74 09/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
29/09/26 Buy

Chief Executive Officer

2,06,813 0.4281%
28/09/26 Buy

Chief Executive Officer

93,091 0.1927%
24/11/25 Buy

Director

8,600 0.0178%
Change 5-day change 1-year change 3-year change Capi.($)
+2.34%-0.48%-82.73%-97.87% 2.36Cr
+1.15%-2.81%+53.73%+71.00% 6.56TCr
-2.76%-1.27%+7.67%+88.64% 6.04TCr
-0.78%+0.73%+23.43%+87.55% 5.58TCr
-0.16%-3.37%+8.78%+119.23% 4.7TCr
-1.45%-4.60%+21.45%+28.17% 4.36TCr
-0.70%+1.43%+14.05%+45.20% 3.67TCr
-1.91%-15.48%+136.00%+664.98% 3.61TCr
-0.23%-1.82%+77.98%+58.59% 3.29TCr
-2.49%+0.54%-39.14%+384.00% 2.7TCr
Average -0.71%-1.99%+22.12%+144.95% 4TCr
Weighted average by Cap. -0.94%-1.48%+33.51%+147.30%

Financials

2026 *2027 *
Net sales - -
Net income -4.25Cr -3.86Cr -3.56Cr -3.22Cr -6.07Cr -398.62Cr -6.29Cr -43Cr -17Cr -213.91Cr -16Cr -16Cr -677.58Cr -6Cr -5.45Cr -5.04Cr -4.55Cr -8.59Cr -563.38Cr -8.89Cr -61Cr -24Cr -302.33Cr -23Cr -22Cr -957.65Cr
Net Debt - -
Projected Income Statement - Annual - Filana Therapeutics, Inc.
Logo Filana Therapeutics, Inc.
Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Employees
19
Date Price Change Volume
17/26/17 $0.4800 +2.13% 1,48,077
16/26/16 $0.4700 +10.56% 12,80,879
13/26/13 $0.4251 -5.11% 3,20,074
12/26/12 $0.4480 -7.07% 4,32,526
11/26/11 $0.4821 -0.04% 2,17,174
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Filana Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.4700USD
Average target price
6.500USD
Spread / Average Target
+1,282.98%
  1. Stock Market
  2. Stocks
  3. FLNA Stock